Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Participation in a cervical cancer screening program in a safety-net health system more than doubled when patients received ...

Global Akeega sales will reach $676 million by 2030, while Talzenna and saruparib reach $618 million and $628 million ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

A new study, sponsored by AstraZeneca and presented at the American Society of Clinical Oncology (ASCO) annual meeting in ...

An analysis of the CALLA study shows that ctDNA is detected an average of 5.5 months before radiographic progression.

A new multinational study analyzing data from over 230 million people across 20 global sites highlights the relationship ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...

A global study, covering more than 230 million people, sheds light on the relationship between Guillain-Barré syndrome after ...